Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts
Low density lipoprotein cholesterol (LDL-C) is the target of lipid lowering therapy in subjects who have atherosclerotic cardiovascular disease (ASCVD) or who are at risk of developing it. There have been many debatable issues in this field. Should lifelong statins be prescribed for subjects at low...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| Series: | Journal of Clinical and Preventive Cardiology |
| Subjects: | |
| Online Access: | http://www.jcpconline.org/article.asp?issn=2250-3528;year=2016;volume=5;issue=4;spage=125;epage=129;aulast=Iyengar |
| _version_ | 1811307413683306496 |
|---|---|
| author | Shamanna S Iyengar |
| author_facet | Shamanna S Iyengar |
| author_sort | Shamanna S Iyengar |
| collection | DOAJ |
| description | Low density lipoprotein cholesterol (LDL-C) is the target of lipid lowering therapy in subjects who have atherosclerotic cardiovascular disease (ASCVD) or who are at risk of developing it. There have been many debatable issues in this field. Should lifelong statins be prescribed for subjects at low risk of ASCVD in primary prevention? How low one can go in LDL-C lowering and is it safe? Should we "treat to target" or just administer high or moderate or low intensity statins based on the risk category? What is the role of nonstatin drugs in lipid lowering therapy? Are proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9 inhibitors) going to be the game changers? There is an abundance of literature looking at these matters. Statins continue to be the first choice in dyslipidemia management. PCSK9 inhibitors would be a welcome addition to the armamentarium or an attractive alternative in certain situations. |
| first_indexed | 2024-04-13T09:03:55Z |
| format | Article |
| id | doaj.art-fc927a547fb84c21847342d3bd4cf6fa |
| institution | Directory Open Access Journal |
| issn | 2250-3528 |
| language | English |
| last_indexed | 2024-04-13T09:03:55Z |
| publishDate | 2016-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Clinical and Preventive Cardiology |
| spelling | doaj.art-fc927a547fb84c21847342d3bd4cf6fa2022-12-22T02:53:03ZengWolters Kluwer Medknow PublicationsJournal of Clinical and Preventive Cardiology2250-35282016-01-015412512910.4103/2250-3528.192689Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer conceptsShamanna S IyengarLow density lipoprotein cholesterol (LDL-C) is the target of lipid lowering therapy in subjects who have atherosclerotic cardiovascular disease (ASCVD) or who are at risk of developing it. There have been many debatable issues in this field. Should lifelong statins be prescribed for subjects at low risk of ASCVD in primary prevention? How low one can go in LDL-C lowering and is it safe? Should we "treat to target" or just administer high or moderate or low intensity statins based on the risk category? What is the role of nonstatin drugs in lipid lowering therapy? Are proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9 inhibitors) going to be the game changers? There is an abundance of literature looking at these matters. Statins continue to be the first choice in dyslipidemia management. PCSK9 inhibitors would be a welcome addition to the armamentarium or an attractive alternative in certain situations.http://www.jcpconline.org/article.asp?issn=2250-3528;year=2016;volume=5;issue=4;spage=125;epage=129;aulast=IyengarAtherosclerotic vascular diseaselow density lipoprotein cholesterolnonstatinsproprotein convertase subtilisin/kexin type 9 inhibitorsstatins |
| spellingShingle | Shamanna S Iyengar Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts Journal of Clinical and Preventive Cardiology Atherosclerotic vascular disease low density lipoprotein cholesterol nonstatins proprotein convertase subtilisin/kexin type 9 inhibitors statins |
| title | Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts |
| title_full | Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts |
| title_fullStr | Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts |
| title_full_unstemmed | Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts |
| title_short | Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts |
| title_sort | low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease newer concepts |
| topic | Atherosclerotic vascular disease low density lipoprotein cholesterol nonstatins proprotein convertase subtilisin/kexin type 9 inhibitors statins |
| url | http://www.jcpconline.org/article.asp?issn=2250-3528;year=2016;volume=5;issue=4;spage=125;epage=129;aulast=Iyengar |
| work_keys_str_mv | AT shamannasiyengar lowdensitylipoproteincholesterolreductionforthepreventionofcardiovasculardiseasenewerconcepts |